Lack of EC-SOD worsens alveolar and vascular development in a neonatal mouse model of bleomycin-induced bronchopulmonary dysplasia and pulmonary hypertension

Pediatr Res. 2015 Dec;78(6):634-40. doi: 10.1038/pr.2015.166. Epub 2015 Aug 31.

Abstract

Background: Pulmonary hypertension (PH) worsens clinical outcomes in former preterm infants with bronchopulmonary dysplasia (BPD). Oxidant stress disrupts alveolar and vascular development in models of BPD. Bleomycin causes oxidative stress and induces BPD and PAH in neonatal rats. Disruption in the vascular endothelial growth factor (VEGF) and nitric oxide signaling pathways contributes to BPD. We hypothesized that loss of EC-SOD would worsen PAH associated with BPD in a neonatal mouse model of bleomycin-induced BPD by disrupting the VEGF/NO signaling pathway.

Methods: Neonatal wild-type mice (WT), and mice lacking EC-SOD (EC-SOD KO) received intraperitoneal bleomycin (2 units/kg) or phosphate-buffered saline (PBS) three times weekly and were evaluated at weeks 3 or 4.

Results: Lack of EC-SOD impaired alveolar development and resulted in PH (elevated right ventricular systolic pressures, right ventricular hypertrophy (RVH)), decreased vessel density, and increased small vessel muscularization. Exposure to bleomycin further impaired alveolar development, worsened RVH and vascular remodeling. Lack of EC-SOD and bleomycin treatment decreased lung total and phosphorylated VEGFR2 and eNOS protein expression.

Conclusion: EC-SOD is critical in preserving normal lung development and loss of EC-SOD results in disrupted alveolar development, PAH and vascular remodeling at baseline, which is further worsened with bleomycin and associated with decreased activation of VEGFR2.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Bleomycin*
  • Bronchopulmonary Dysplasia / chemically induced
  • Bronchopulmonary Dysplasia / enzymology*
  • Bronchopulmonary Dysplasia / genetics
  • Bronchopulmonary Dysplasia / pathology
  • Bronchopulmonary Dysplasia / physiopathology
  • Endothelial Cells / enzymology*
  • Endothelial Cells / pathology
  • Genetic Predisposition to Disease
  • Hypertension, Pulmonary / chemically induced
  • Hypertension, Pulmonary / enzymology*
  • Hypertension, Pulmonary / genetics
  • Hypertension, Pulmonary / pathology
  • Hypertension, Pulmonary / physiopathology
  • Hypertrophy, Right Ventricular / chemically induced
  • Hypertrophy, Right Ventricular / enzymology
  • Hypertrophy, Right Ventricular / genetics
  • Hypertrophy, Right Ventricular / physiopathology
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidative Stress
  • Phenotype
  • Phosphorylation
  • Pulmonary Alveoli / blood supply*
  • Pulmonary Alveoli / enzymology*
  • Pulmonary Alveoli / pathology
  • Pulmonary Artery / enzymology*
  • Pulmonary Artery / pathology
  • Pulmonary Artery / physiopathology
  • Signal Transduction
  • Superoxide Dismutase / deficiency*
  • Superoxide Dismutase / genetics
  • Vascular Endothelial Growth Factor A / metabolism
  • Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • Vascular Remodeling*
  • Ventricular Dysfunction, Right / chemically induced
  • Ventricular Dysfunction, Right / enzymology
  • Ventricular Dysfunction, Right / genetics
  • Ventricular Dysfunction, Right / physiopathology
  • Ventricular Function, Right
  • Ventricular Pressure

Substances

  • Vascular Endothelial Growth Factor A
  • vascular endothelial growth factor A, mouse
  • Bleomycin
  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • Superoxide Dismutase
  • Kdr protein, mouse
  • Vascular Endothelial Growth Factor Receptor-2